简体
Facebook
Twitter
LinkedIn
Instagram
YouTube
關於我們
聯繫我們
所有新聞
澳門
大灣區
中國
全球
葡語國家
商業
金融
時事
社論
時事評論
特別報導
典藏
Teva
Clinical Study
,
GlobeNewswire
,
Health
,
Pharmaceuticals
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOB
01/27/2025
Calendar of Events
,
GlobeNewswire
,
Health
,
Pharmaceuticals
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
IMPACT-TD Registry, the largest study evaluating holistic ef
11/01/2024
Clinical Study
,
GlobeNewswire
,
Health
,
Pharmaceuticals
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-‘749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
Teva’s presentation of findings from six schizophrenia studi
11/01/2024
GlobeNewswire
,
Health
,
Partnerships
,
Pharmaceuticals
,
Product / Services Announcement
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for
10/22/2024
GlobeNewswire
,
Health
,
Pharmaceuticals
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Prolia® (denosumab) is indicated to treat certain conditions
10/08/2024
GlobeNewswire
,
Health
,
Partnerships
,
Pharmaceuticals
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
The expansion of the strategic partnership reinforces the so
10/03/2024
Clinical Study
,
GlobeNewswire
,
Pharmaceuticals
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researchin
09/21/2024
Clinical Study
,
GlobeNewswire
,
Pharmaceuticals
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helpi
09/21/2024
時事評論
【總監之言】以人為本
這是一道簡單的數學題:受到低出生率的影響,加上預期壽命不負眾望的增加,澳門人口老化給城市經濟的長期發展製造了巨大的挑戰。
馬天龍
02/15/2025
【時事評論】先宜居 再宜商 繼宜遊
2024年大家都辛苦了,2025年會好一點嗎?現實告訴我們,2025年仍是個艱難年頭,簡單說就是兩句話,不要指望某一、兩項政策出來,全澳門經濟尤其中小企就能反彈,數據顯示不到的失業、就業不足就會解決;不要指望政府能有上帝之手,今年必須靠自己,無論中小企還是打工仔。
甄慶悅
02/13/2025
【時事評論】澳門過度旅遊帶來的挑戰
澳門,新年快樂!這座城市擁有驚人的GDP數字,庫房收入持續膨脹,且與中國內地和葡語國家的連結不斷延伸。這些都預示著新的一年將充滿了前瞻性發展。樂觀的意念在城中營造了一派其樂融融、欣欣向榮的氛圍,一切都超越了那貪婪的夢想。這座城市張開了雙臂,熱情地擁抱來自世界各地的旅客和企業。在城市旅遊景點不斷增加的背景下,盤滿缽滿的新年願望越顯清晰。新年許下的承諾發出比北極星更耀眼的光芒。
Keith Morrison
02/13/2025